You just read:

The EMA and FDA Grant Orphan Drug Designation to Pharnext's PXT-3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A

News provided by

Pharnext SAS

Jun 23, 2014, 02:00 ET